丰富的一年配料

Ingredients fora Deal-rich Year What’s the recipe for a deal-rich year in global biopharma R&D?A dash of growth, a generous amount of mid-size expansion, equal portionsof internal and external innovation, and a pinch of positivity. Global Biopharma R&D Pipeline Total size has grown by 7.2%; 22,825 drugs under development Global Biopharma R&D Pipeline Large pharma share diminishes; expansion driven by mid-size companies Large Pharma R&D Strategy Portfolios generally align to 50:50 internal vs. external innovation Industry Patent Cliff and Growth Gap More than $200bn of industry revenues entering loss of exclusivity crosshairs •Significant patentcliff approaching •Businessdevelopmentcritical to replacelost revenues Source: Evaluate, World Preview 2023 M&A Activity Copyright © 2023 Pharma Intelligence UK Limited (Citeline), a Norstella company. Pharma Intelligence UK Limited is a company registered in Englandand Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James’s Square, London, England, SW1Y 4LB C TELINE.COM